CONCORD, Calif. -- Cerus Corporation (NASDAQ:CERS) announced today the submission of a CE Mark application for approval to market the INTERCEPT Blood System for plasma in Europe. The system, which is being jointly developed by Cerus and Baxter Healthcare Corporation, is designed to reduce the risk of transfusion-transm
BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that it has taken several actions in response to recent reports that specific clinical sites in San Francisco and New York City and the L.A. Gay and Lesbian Center have recently experienced an increased level of false positive results using the
LAS VEGAS -- Samaritan Pharmaceuticals Inc. (AMEX:LIV): -- Pre-clinical and Clinical Studies Suggest SP-01A Prevents HIV Virus from Entering Human Cell -- Drug Resistance is the Most Common Cause of Treatment Failure with Current Antiretroviral Therapy Regimes -- With Encouraging Clinical Data SP-01A Could Be Life Savi
-- AmBiLoad Study Evaluated Optimum Use of AmBisome for Patients With Life-Threatening Infections ATLANTA -- Gilead Sciences , Inc. (Nasdaq:GILD) today announced results from its clinical trial known as AmBiLoad, which compared a 3 mg/kg/day treatment course of AmBisome(R) (amphotericin B) liposome for injection versus
ST. LOUIS -- Dr. Milos Opravil, a preeminent physician and researcher, has been named by Thomas Land Publishers as the Editor-in-Chief of the independent journal HIV Clinical Trials (HCT), effective January 1, 2006. Dr. Opravil will succeed Dr. Maurice Staquet, HCT s founding Editor-in-Chief, who will continue to serve
WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (Nasdaq:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced that its lead product candidate, the oral HIV maturation inhibitor PA-457, will be the subject of two oral presentations at the 45th Ann
FOSTER CITY, Calif. -- Gilead Sciences , Inc. (Nasdaq:GILD) today announced the launch of www.ChangeofHAART.com, a new educational website featuring information about advances in HIV treatment -- also called Highly Active Antiretroviral Therapy or HAART -- for people living with HIV/AIDS. The site includes resources ab
-- Progenics CEO to Ring Nasdaq s Opening Bell Today in Honor of World AIDS Day TARRYTOWN, N.Y.-- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced that it is today initiating a phase 1b clinical trial of a new investigational HIV therapy - a humanized monoclonal antibody that specifically binds CCR5, a receptor
NEW ROCHELLE, N.Y.-- In honor of World AIDS Day, and in view of the ongoing urgent need to disseminate authoritative information in this field, publisher Mary Ann Liebert, Inc. will provide free access to all archival online issues of the company s AIDS journals through the end of December. Free online access is availa
LA JOLLA, Calif. -- Amphora(TM) (clinically known as Acidform) was selected by the U.S. Centers for Disease Control and Prevention (CDC), the United States Agency for International Development (USAID), the Contraceptive Research and Development (CONRAD), and the University of North Carolina at Chapel Hill (UNC-CH) to b
BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced it will participate in opening the NASDAQ Stock Market and donate up to 100,000 OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Test kits to several African countries and to
SAN CARLOS, Calif. -- NeurogesX, Inc., a privately held specialty pharmaceutical company focused on the development and commercialization of novel treatments for relief of neuropathic pain, today announced that it has completed a $20 million private equity financing. The company believes that proceeds from this financi
BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, announced today the launch of its OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody test in Mexico . OraQuick(R) ADVANCE(TM) is the only FDA approved and CLIA waived oral fluid rapid HIV-1/2 test currently available in
GABORONE, Botswana -- International expansion of Bicycling s acclaimed BikeTown program will deliver 200 specially-designed bikes to health care workers in Botswana to assist in HIV and AIDS care Bicycling magazine Editor-In-Chief Steve Madden and Publisher Chris Lambiase announced today that the magazine will partner
SANTA FE, N.M. -- CytoDyn, Inc. (OTCBB:CYDY) has tapped Jacob P. Lalezari, MD at Quest Clinical Research in San Francisco, California, as Principal Investigator for the next study of Cytolin(R), a targeted immune therapy for HIV/AIDS, pending FDA approval. Quest Clinical Research has conducted clinical trials for Merck
SEATTLE -- Targeted Genetics Corporation (Nasdaq:TGEN) and its scientific collaborators at The Children s Hospital of Philadelphia and Columbus Children s Research Institute (CCRI) today announced that the National Institute of Allergy and Infectious Disease (NIAID) has awarded a $21.75 million contract to expand AAV-b
WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (Nasdaq:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, will present at the Lazard Capital Markets Annual Life Sciences Conference to be held at the New York Palace hotel in New York, NY on November 29-30. Pa
BOYNTON BEACH, Fla. -- Nutra Pharma Corp. (OTCBB:NPHC), a biopharmaceutical and diagnostics company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases, announced today that
SOUTH JORDAN, Utah -- ISIPS, the first international needlestick prevention group, announced that six recipients are being honored for reducing sharps injuries with a Sharps Injury Prevention Award with an additional 34 recipients receiving honorable mention awards. These awards are part of the International Sharps Inj
OAK BROOK, Ill. -- Bio-Bridge Science, Inc. (OTCBB: BGES) today announced that it has entered into an exclusive distribution agreement with Xinhua Surgical Instruments Co., Ltd., located in Shandong, China . Under the agreement, Bio-Bridge Science has been granted exclusive distribution rights for all Xinhua surgical i
DUBLIN, Ireland -- Merck & Co. , Inc. -- In a 10-day monotherapy trial, patients taking MK-0518 achieved a 98 percent reduction in HIV-RNA across all dosages tested, and at least half achieved HIV-RNA copies of 400 per mL or less Initial phase ll clinical trial results presented at the European AIDS Cl
SANTA FE, N.M. -- The common stock of CytoDyn, Inc.(OTCBB:CYDY) is now trading on the Over The Counter Bulletin Board under the symbol CYDY.OB. CytoDyn is developing a family of targeted immune therapies for treating HIV/AIDS. Although targeted immune therapies are now a mainstream approach to treating cancer and autoi
DUBLIN, Ireland -- Gilead Sciences , Inc. (Nasdaq:GILD) today announced the presentation of preliminary 24-week data from the COMET (Combination of Efavirenz and Truvada) study at the 10th European AIDS Conference (EACS), November 17-2
LAS VEGAS -- Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, announced today, its CEO Dr. Janet Greeson recently granted the Wall Street Transcript an exclusive interview profiling Samaritan, and an update on its most recent corporate accomplishments, including discussions on the following to
----California Healthcare Institute: Who: -- George Shultz, former U.S. Secretary of State; Distinguished Fellow, Hoover Institution -- Richard Preston, Author, The Hot Zone, The Demon in the Freezer and The Cobra Event -- Scott Gottlieb, M.D., FDA Deputy Commissioner for Medical and Scientific Affairs -- Howard
SAVANNAH, Ga. -- University of Miami to Acquire HDC s Recently Discovered AIDS Biomarker Signature and Agrees to Continuing Royalty Payments for Any Future Commercial Sales related to Biomarkers Health Discovery Corporation announced today that the University of Miami will acquire full ownership of the recent AIDS Biom
BLUE BELL, Pa. - Locus Pharmaceuticals, Inc. announced today that it has agreed to license from Cornell Research Foundation a second proprietary crystal structure of the fusion protein gp41, a novel drug target for the treatment of HIV/AIDS. Locus plans to apply its proprietary computational technologies to this new st
SEATTLE & NEW YORK -- Targeted Genetics Corporation (NASDAQ:TGEN) and The International AIDS Vaccine Initiative (IAVI) today announced the start of a Phase II trial in South Africa to test the safety and immunogenicity of tgAAC09, a preventive HIV vaccine candidate that is based on HIV subtype C, the subtype of the
LEBANON, Tenn. - Hartmann Inc., one of the country s oldest luggage and leather goods manufacturers, announced today that it has joined the fight against AIDS by partnering with the National AIDS Fund and Kimpton Hotels. As part of its contribution, Hartmann created special, full-grain leather, red coaster set embossed
OAK BROOK, Ill.-- Bio-Bridge-Science Inc. (BGES.OB) announced that CEO Dr. Liang Qiao is featured in an interview with the Wall Street Reporter Senior Analyst Ian Roberts. The topics of discussion include the company s unique technology platform and its promising new HIV vaccine. Dr. Qiao also elaborates upon Bio-Bridg
NEW YORK -- Charitable trust Reuters Foundation will host a panel debate, Fighting HIV/AIDS - Does it take more than money? in New York City on Thursday 10th November. The debate will be chaired by Niall FitzGerald, Chairman of Reuters, and the panel will feature: Zackie Achmat, South African AIDS activist Dr Mark Dybu
LITTLE ELM, Texas -- Retractable Technologies, Inc. (AMEX:RVP) announced today that it has been awarded its second major U.S. government contract to provide VanishPoint(R) safety syringes under the Bush Administration s Global HIV/AIDS initiative (President s Emergency Plan for AIDS Relief). Under the contract, awarded
CARLSBAD, Calif. -- The Immune Response Corporation (Nasdaq Capital Market:IMNR) announced today the appointment of Joseph F. O Neill, M.D., M.P.H. as its new Chief Executive Officer and President, succeeding John N. Bonfiglio, Ph.D. Dr. O Neill comes to The Immune Response Corporation after a distinguished career lead
JOHANNESBURG, South Africa , LONDON & NEW YORK -- Clear Channel Communications, Inc. (NYSE:CCU) -- Whoopi Goldberg, Sir Roger Moore, Lord Richard Attenborough and Yvonne Chaka Chaka Unveil Outdoor Ads at Same-Day Events in New York, London and Johannesburg -- Joint campaign from UNICEF and Clear Channel Outdoor wil
LAS VEGAS -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced today its strategy to build a European marketing and sales engine to transform the economic performance of the Company. Samaritan is establishing its European headquarters in Athens, Gree
KEY WEST, Fla.-- The annual Key West AIDS Help fundraiser is making a last minute appeal to the gay community for donations. After two hurricanes the efforts are in bad shape, causing concern over funding for HIV infected patient s housing, health care. Now to add insult to injury, forecasters expect Hurricane Wilma to
SAN DIEGO-- Inovio Biomedical Corporation (AMEX:INO), a late stage developer of oncology and other therapies using electroporation to deliver drugs and nucleic acids, announced today that two articles presenting study results relating to gene-based therapies for HIV and vascular disease were published in peer-reviewed
SAN DIEGO -- Inovio Biomedical Corporation (AMEX:INO), a late stage developer of oncology and other therapies using electroporation to deliver drugs and nucleic acids, announced today that two articles presenting study results relating to gene-based therapies for HIV and vascular disease were published in peer-reviewed
BASKING RIDGE, N.J. -- New Website www.resurgex.com Will Serve as a Nutritional Resource for Consumers and Professionals While Providing Millennium a Worldwide E-Commerce Solution Millennium Biotechnologies, Inc., (OTCBB: MBTG), a research-based nutraceutical company and a pioneer in the emerging field of specialized n
BETHLEHEM, Pa.-- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, announced today that it will present at a meeting of the Blood Products Advisory Committee ( BPAC ) of the U.S. Food and Drug Administration ( FDA ) in Gaithersburg, Maryland on November 3, 2005. The public meeting w
GAITHERSBURG, Md.-- GenVec, Inc. (Nasdaq:GNVC) announced today that the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, has begun Phase II clinical testing of an experimental adenovector-based HIV vaccine candidate developed in collabora
HOUSTON -- PhotoImmune Biotechnology, Inc. has announced that it will be presenting at 9:45 a.m., Tuesday, October 11th at Medtech Insight s Investment In Innovation (In3) BOSTON: A Preview of Early-Stage Medical Technology Companies Conference, taking place October 10-11, 2005 at The Westin Copley Place Hotel in Bosto
GAITHERSBURG, Md. -- GenVec, Inc. (Nasdaq:GNVC) announced today that it has received a $9.9 million increase in funding for its HIV vaccine development work with the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health. The VRC will utilize Ge
ATHENS, Greece -- Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, announced today, that Eugene Boyle, CFO of Samaritan Pharmaceuticals, and Dr. Christos Dakas, Managing Director of Samaritan Pharmaceuticals Europe, will showcase the importance and uniqueness of its technology to major pharmac
EMERSON, N.J. -- Energex Systems, Inc. announced today that results of a clinical trial on rhesus macaque monkeys infected with the Simian Immunodeficiency Virus (SIV) established that the Company s ultraviolet light technology was safe and effective in increasing cell mediated immunity against the virus and in reducin
DURHAM, N.C. -- Constella Group, a leading global provider of professional health services, has won a contract with a total potential value of $325 million, including an initial $100 million task order with the United States Agency for International Development (USAID). Through this contract, the company will continue
LOS ANGELES-- On Thursday, September 29, Governor Arnold Schwarzenegger signed historic legislation designed to address the disproportionate impact of HIV/AIDS on the health of African Americans in five designated regions: Los Angeles, the Inland Empire, Sacramento and the Central Valley, San Diego and the San Francisc
PARIS -- BioAlliance Pharma, a biopharmaceutical company focused on the development of innovative therapeutics in the field of drug resistance, announced today that it has filed a marketing authorization application (MAA) with the French Health Products Safety Agency (AFSSAPS) to initiate the approval process within th
-- Getty Images CEO Jonathan Klein Participating in Congressional Briefing With Goal of Improving Public/Private Sector Global AIDS Partnership SEATTLE -- Getty Images, Inc. (NYSE:GYI), the world s leading creator and distributor of imagery, will today receive the 2005 Business Excellence Award for Innovation from the
WILMINGTON, Del. -- Incyte Corporation (NASDAQ:INCY) announced today that it met with representatives from the FDA yesterday regarding the development of Reverset, Incyte s nucleoside reverse transcriptase inhibitor (NRTI) that is being developed as a therapy for treatment-experienced HIV patients. The purpose of t
-- BioForm Medical to File Radiesse(TM) for Facial Soft Tissue Approval SAN MATEO, Calif.-- BioForm Medical, Inc., announced today that 100% of patients enrolled in a clinical study of Radiesse(TM) to correct facial wasting reported a significant improvement in their appearance at 12 months post treatment. The results
CARLSBAD, Calif. -- The Immune Response Corporation (Nasdaq: IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS), announced today it will begin enrolling patients, in Italy , in a Phase I/II study investigating IR103, the Company s newest pr
SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD) announced today that human clinical trials to treat patients infected with the Hepatitis-C virus (HCV) are now underway at the Apollo Hospital in New Delhi, India . The primary objective of the trial is to demonstrate the safety of Aethlon s Hemopurifier(TM) treatment tec
CARLSBAD, Calif. -- The Immune Response Corporation (Nasdaq:IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS), held an investor conference call today to update investors on the regulatory strategy for initiation of a multi-center Phase III
BOYNTON BEACH, Fla. -- Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology holding company that owns rights to intellectual property related to the development of drugs for Multiple Sclerosis and HIV, has announced that its minority holding, ReceptoPharm, Inc., has completed a study of RPI-MN indicating that the drug is e
-- Company Receives $10.1 Million NIH Grant for PRO 140 Development NEW YORK -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced positive phase 1 clinical findings regarding its investigational drug, PRO 140, a novel HIV entry inhibitor. PRO 140 is a humanized monoclonal antibody against CCR5 that is desig
KEY WEST, Fla. -- The annual Key West King and Queen of Fantasy Fest fundraising efforts got off to a slow start, causing concern over next year s funding for housing, health care. Hurricane Katrina sideswiped Key West on August 26th, postponing the kick off for the King and Queen of Fantasy Fest fundraising campaign t
FOSTER CITY, Calif. -- Gilead Sciences , Inc. (Nasdaq:GILD) today announced a significant price reduction for Viread (R) ( tenofovir disoproxil fumarate) and Truvada(R) (emtricitabine and tenofovir disoproxil fumarate) made
NEW YORK -- Macy s is seeing stars this back-to-school season with its first-ever celebrity fashion auction. The charity auction will benefit YouthAIDS, the global initiative that raises awareness and funds for AIDS prevention and education in high-risk youth. Starting on Monday, August 22nd, denim divas of all ages wi
LAS VEGAS-- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced today that it is listed in the leading BioCentury, The Bernstein Report on BioBusiness, in an article titled NO entry, as being a contender in the race for approval as an oral HIV entry inhibitor. Samaritan was listed thir
LITTLE ELM, Texas -- In a landmark contract aimed at eliminating the spread of HIV/AIDS and other bloodborne diseases via contaminated needles in China, Retractable Technologies, Inc. (AMEX:RVP) announced today that it has signed a licensing agreement with a government-designated medical device maker to produce about 4
AUSTIN, Texas -- LabNow, Inc., an innovative provider of lab-on-a-chip technology, has announced the appointment of former Senator Bill Bradley to the company s Board of Directors. Rick Hawkins, Chairman and CEO of LabNow, expressed his excitement regarding Senator Bill Bradley s appointment. Senator Bradley brings a w
STAMFORD, Conn.-- Preliminary experimental data from cellular tests conducted by university scientists working under a research grant sponsored by Marc Pharmaceuticals, Inc. (OTC:MPMA) (OTC:MPMAW) (OTC:MPMAZ) has demonstrated that a betulinol derivative inhibits HIV-1 replication by more than 90 percent with no evidenc
BETHLEHEM, Pa.-- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, announced today that it has received a worldwide, non-exclusive license from Ortho-Clinical Diagnostics and Chiron Corporation to patents relating to the hepatitis C ( HCV ) virus. Under the terms of the l
CARLSBAD, Calif. -- The Immune Response Corporation (Nasdaq: IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS), announced that results from a Phase II trial with REMUNE(R), conducted in Spain , were presented in two posters at today s sess
MEDFORD, N.Y. -- Chembio Diagnostics, Inc. (OTCBB:CEMI) announced today that Dr. James J. Koziarz has joined its newly formed Advisory Board. The Advisory Board members are individuals who have held leadership positions in research, diagnostic product development, and public health, and who support Chembio s goal of en
SAN DIEGO -- ADVENTRX Pharmaceuticals, Inc. (Amex:ANX) today announced data from an in vitro study indicating that Thiovir(TM), the Company s non-nucleoside reverse transcriptase inhibitor (NNRTI), demonstrated effectiveness against human immunodeficiency virus type-1 (HIV-1), which is resistant to other NNRTIs and nuc
CARLSBAD, Calif. -- The Immune Response Corporation (Nasdaq:IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS), announced that the first clinical trial data with IR103, the Company s newest immune-based therapy candidate, were presented as
RIO DE JANEIRO, Brazil -- Incyte Corporation (Nasdaq:INCY) today announced positive results from Study 203, a six-month randomized double-blind Phase IIb trial, involving 199 patients and 25 clinical sites in the U.S. and Europe to evaluate the efficacy, dose response, safety and tolerability of Reverset in treatment-e
NEW YORK -- Xenomics, Inc. (OTCBB:XNOM), a developer of next-generation medical DNA technologies, announced today that it will present new research data that demonstrates new, higher level of sensitivity of its Transrenal-DNA (Tr-DNA) technology platform for the safe, simple and accurate detection of HIV in AIDS patien
NEW YORK -- NanoViricides, Inc. (Pink Sheets:NNVC), has announced the online availability of a feature article about NanoViricides, Inc. in the July 13, 2005 edition of NanoBiotech News. In the article, Dr. Diwan discusses NanoViricides uniqueness and drug development goals as it prepares to compete in the multi-billio
OREGON CITY, Ore. -- The Hepatitis C Caring Ambassadors Program (HCCAP) announced that they had received notification on July 19th from the office of Oregon Governor Ted Kulongoski that he had vetoed hepatitis C legislation overwhelmingly passed by both the Oregon House and Senate. The legislation, HB 2480, would have
CARLSBAD, Calif. -- The Immune Response Corporation (Nasdaq: IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis, today announced that it has entered into a Standby Equity Distribution Agreement (SEDA) with Cornell Capital Partners, LP, to suppor
LAS VEGAS -- Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs announced today that it has commenced dosing the first patient on the Phase II monotherapy trial of its lead oral entry inhibitor anti-viral agent SP01A in HIV-infected patients. Positive results in an earlier clinical trial provided
-- Antiretroviral Activity and Tolerability of Reverset(TM) (D-d4FC) Demonstrated with Combination Therapy in Treatment-Experienced Patients WILMINGTON, Del. -- Incyte Corporation (Nasdaq:INCY) today announced that an abstract describing results from the Phase IIb study of Reverset has been accepted for both oral and p
DUBLIN, Ireland -- To provide a comprehensive resource to companies, investors, and entrepreneurs interested either in accessing China s market for antibody products or cost effective production of antibodies for therapeutic, diagnostic, or laboratory use. Overview and analysis of the antibody industry in China, includ
FOSTER CITY, Calif. -- Gilead Sciences , Inc. (Nasdaq:GILD) today announced that it has begun enrolling patients in a Phase I/II study of the company s oral HIV integrase inhibitor, GS 9137 (also known as JTK-303) for the treatment of HIV. This double-blind, randomized, placebo-controlled Phase I/II dose-escalation stu
NEW YORK -- Xenomics, Inc. (OTCBB:XNOM), a developer of next-generation medical DNA technologies, announced today that it has been accepted to present a report on application of its Transrenal-DNA (Tr-DNA) technology platform for diagnosis of infectious diseases at next month s annual meeting of the American Associatio
MEDFORD, N.Y. -- Chembio Diagnostics, Inc. (OTCBB: CEMI) announced today that it has filed a second new patent application with the United States Patent and Trademark Office for a novel method and device for rapid testing incorporating a form of lateral flow technology. The Company believes that this patent application
SAN CARLOS, Calif. -- NeurogesX, Inc., a privately held specialty pharmaceutical company, today announced that it has initiated patient enrollment in a Phase 3 study to study pain reduction in patients suffering from postherpetic neuralgia (PHN) after a single-application of NGX-4010, NeurogesX s novel high-concentrati
BETHLEHEM, PA. -- OraSure Technologies, Inc. (NASDAQ:OSUR) and the National Association of People with AIDS (NAPWA) announced today the launch of the Mayors Campaign Against HIV, a national campaign to encourage testing for HIV and promote the benefits of knowing one s HIV status. The Campaign is being sponsored by Ora
SAN FRANCISCO -- Joe Skraba, VP of Business Development at LabNow will be presenting information on the LabNow Analyzer and BioChip System at Investment In Innovation (In3). The system is capable of performing rapid, low cost cellular and chemical assays at the point of care. The company, headquartered in Austin, Texas
SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD) announced today that Qualtran LLC, a contract research organization (CRO) managing biocompatibility studies and clinical trials for Aethlon in India , has advised the Company that the Apollo Hospital, New Delhi has been retained as a sponsor site for Aethlon s forthcoming
MIAMI -- Edot.com, Inc. (Pink Sheets:ECMM), announced that Krishna Menon joined the Company s scientific advisory board and accepted the position of Chief Regulatory officer. Dr. Menon is a former employee of the year President s award winner at Eli Lilly , having led several blockbuster drug projects there. I m v
LAS VEGAS -- Samaritan Pharmaceuticals, Inc. (AMEX:LIV), a developer of innovative drugs, announced today that its Phase II double-blind, placebo controlled, multi-dose, monotherapy study in treatment-experience HIV patients, has been expedited as a result of utilizing the services of CROfessionals. Samaritan s lead or
NEW YORK -- Xenomics, Inc. (OTCBB:XNOM), a developer of next-generation medical DNA technologies, announced today that it has filed a U.S. patent application for its breakthrough technology enabling the detection of HIV based on its proprietary Transrenal DNA (Tr-DNA) technology which uses simple, easily obtained urine
WHAT: Approximately 57,000 people live with HIV/AIDS in Los Angeles County, including an estimated 12,000 to 15,000 people who are unaware they are infected with the virus, according to the County of Los Angeles, Department of Health Services, Office of AIDS Programs and Policy (OAPP). To increase HIV counseling, educa
CONCORD, Calif. -- Cerus Corporation (NASDAQ:CERS) today announced that it has entered into a definitive agreement with BioOne Corporation for commercialization of the INTERCEPT Blood System for plasma in parts of Asia. Certain direct and indirect subsidiaries of Baxter International Inc. were also parties to the trans
HOUSTON -- CytoGenix Inc. (OTCBB:CYGX) today announced that the Company is presently featured in an online interview at http://www.PRBroadcast.com. CEO Malcolm Skolnick discusses the Company s recent HIV Vaccine License with the NIH, proprietary DNA vaccine as well as other matters impacting the future performance of t
LINCOLN, Neb. -- Nature Technology Corporation (NTC) announced positive results from two projects aimed at increasing the effectiveness and productivity of DNA vaccines, respectively. The results will be presented this week at the American Society of Gene Therapy, in St. Louis, MO. DNA vaccines represent a bold new way
CARLSBAD, Calif. -- The Immune Response Corporation (Nasdaq:IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS), announced today that a new arm of a Phase I/II clinical trial investigating IR103, the Company s newest product candidate for th
NEW YORK -- Xenomics, Inc. (OTCBB:XNOM), a developer of next-generation medical DNA technologies, announced today that it has filed a US patent for breakthrough technology enabling the improved detection of tuberculosis based on its proprietary Transrenal DNA (Tr-DNA) technology which uses simple, easily obtained urine
HOUSTON -- CytoGenix, Inc. (OTCBB:CYGX.OB) announced today that it has obtained a commercial evaluation license from the National Institutes of Health (NIH) for a DNA plasmid developed by scientists from the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC). This license gives
SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD) today reported new data related to the safe use of the Hemopurifier(TM) treatment technology in animal studies. Researchers documented that the Hemopurifier, which has been developed to treat individuals infected with HIV (the AIDS virus), Hepatitis-C (HCV), and bioweapon
SAN CARLOS, Calif. -- NeurogesX Inc., a privately held specialty pharmaceutical company, today announced positive results from a multi-center, randomized, double blind, controlled Phase 3 trial in 307 patients suffering from painful HIV-associated sensory neuropathy (HIV-AN). The study met its pre-specified primary end
OTTAWA--Variation Biotechnologies Inc. (VBI) has announced that it will be presenting at 10:20am on May 20th at Windhover Information s The Start-Up Forum 2005, taking place May 18-20, 2005 at the Cambridge Marriott in Boston, MA. Francisco Diaz-Mitoma, MD, PhD and CEO of Variation Biotechnologies, will present data va
PHILADELPHIA -- -- Accelerated Evaluation of a Synergistic Cocktail of Eight Different Alpha-Interferons to Potentially Trigger Guardian Angel Genes Hemispherx Biopharma, Inc. (AMEX: HEB) has initiated clinical trials as part of an accelerated evaluation of the experimental bio-therapeutic Alferon LDO (Low Dose Oral In
SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD) announced today that it is the subject of a news article entitled: Aethlon Readies To Launch Viral Device Trials in India , published in the latest issue of the IndUS Business Journal. The article can be found on page one of the online edition at www.indusbusinessjournal.
BOSTON -- Locus Pharmaceuticals, Inc., a computationally-based pharmaceutical company focused on small molecule therapeutics, has announced that it will be presenting on May 19 at 12:20 p.m. at Windhover Information s The Start-Up Forum 2005 , taking place May 18-20, 2005 at the Cambridge Marriott in Boston, MA. Locus
NEW YORK & BEIJING -- The Global Business Coalition on HIV/AIDS (GBC) announced today its support for the collaborative plan by the People s Republic of China Ministry of Health and Merck Co., Inc. to establish a public-private partnership to fight HIV/AIDS in China. The Merck Company Foundation will support the ne
NEW YORK -- Xenomics, Inc. (OTCBB:XNOM), a developer of next-generation medical DNA technologies, has announced the online availability of a corporate video outlining the Company s proprietary Transrenal-DNA technology and its broad applications in the creation of a new class of powerful, safe and completely non-invasi
BEIJING & WHITEHOUSE STATION, N.J. -- The Ministry of Health (MOH) of the People s Republic of China and Merck & Co. , Inc. today officially established the Comprehensive HIV/AIDS Prevention and Control Cooperative Project, a public-private partnership, for HIV/AIDS prevention, treatment and care in China.
-- Global Business Coalition on HIV/AIDS (GBC) Appointed Private Sector Focal Point for the Global Fund to Fight AIDS, TB and Malaria Board of Directors NEW YORK & GENEVA-- Ambassador Richard Holbrooke, President and CEO of the Global Business Coalition on HIV/AIDS (GBC), the pre-eminent organization leading the bu
SAN FRANCISCO -- Mother s Day is taking on a new meaning this year in the Sub-Saharan African country of Malawi , where some 125 village women are mothering and healing their communities through a unique grassroots program making a difference in the struggle against HIV/AIDS. The Malawi Women s Empowerment Project, mad
GAITHERSBURG, Md. -- VIRxSYS Corporation, a private biotechnology company focused on the development of gene therapy treatments for diseases such as HIV/AIDS, today reported completion of the initial protocol-mandated observations in a Phase I clinical trial evaluating the safety and tolerability of the novel HIV gene
STAMFORD, Conn. -- Marc Pharmaceuticals, Inc. (OTC:MPMA)(OTC:MPMAW)(OTC:MPMAZ) today announced that its lead investigator, Dr. Brij Saxena, a professor of endocrinology at the Weill Medical College of Cornell University has been invited to speak at the 14th International Conference on Health and Environment organized b
BASKING RIDGE, N.J. -- Millennium s HIV/AIDS Study to Be Viewed by Over 6,000 Health Professionals from more than 150 Countries at the 3rd International AIDS Society (IAS) Conference Millennium Biotechnologies, Inc., (OTCBB:MBTG), a research-based nutraceutical company and a pioneer in the emerging field of specialized
HAYWARD, Calif.& LOS ANGELES -- Guava Technologies, Inc., a privately held biotechnology and medical device company, and AHF Global Immunity, an international initiative of AIDS Healthcare Foundation, the largest specialized provider of HIV/AIDS medical care in the United States , today announced a partnership aime
FOSTER CITY, Calif. -- Gilead Sciences , Inc. (Nasdaq: GILD) today announced that the company is proceeding with the evaluation of a second formulation of a fixed-dose combination of Truvada(R) (emtricitabine and tenofovir disoproxil fumarate) and Bristol-Myers Squibb s
FOSTER CITY, Calif. & JOHANNESBURG, South Africa -- Gilead Sciences , Inc. (Nasdaq:GILD) and JSE Securities Exchange listed Aspen Pharmacare (APN) today announced that the companies have signed a letter of intent under which they have committed to enter into a non-exclusive licensing and distribution agreement for
SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD) announced that it will begin shipping its Hemopurifier(TM) treatment technology to India today. The Company stated that today s shipment is the first lot of Hemopurifiers that will be sent to support the HIV and Hepatitis-C human studies that were announced in February.
STAMFORD, Conn. -- Marc Pharmaceuticals, Inc. (OTC:MPMA) (OTC:MPMAW) (OTC:MPMAZ) today announced the appointment of Michael G. Palfreyman, Ph.D., D.Sc. as a consultant and chief scientific and development advisor. Dr. Palfreyman has had more than 30 years of experience in the biotechnology and pharmaceutical industries
LAS VEGAS -- Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs announced today that the Samaritan s CEO, Dr. Janet Greeson, will be a featured presenter at the upcoming EdgeWater Research Spring 2005 Small Cap/Micro Cap Conference in Las Vegas to be held April 22-23, 2005. Dr. Greeson will intro
FOSTER CITY, Calif. -- Record Total Revenues of $430.4 Million, Up 39 Percent over First Quarter 2004; HIV Product Sales of $301.4 Million, Up 47 Percent over First Quarter 2004; EPS of $0.34 Per Share
CARLSBAD, Calif.--(BUSINESS WIRE)--April 19, 2005--The Immune Response Corporation (Nasdaq: IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis, announced today a preclinical study demonstrating the potential for a gp120-deleted HIV-1 antigen (a
LAS VEGAS--(BUSINESS WIRE)--April 19, 2005--Samaritan Pharmaceuticals Inc. (AMEX:LIV): -- Focused on Two AIDS/HIV Drug Programs with One in Late-Stage Clinical Development -- Also Highlights Late-Stage Preclinical Programs for Alzheimer s, Adult Stem Cell and Cardiovascular -- Regulatory Filing for Four Innovative Drug
One Million Whole Blood Donations to Be Screened Annually Using Fully Automated PROCLEIX(R) TIGRIS(R) System with the PROCLEIX(R) ULTRIO(TM) Assay EMERYVILLE, Calif. -- Chiron Corporation (Nasdaq:CHIR) today announced that the South African National Blood Service (SANBS) plans to initiate testing of whole blood donatio
SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD) announced today that the Company is featured in an April 2005 report entitled: Major Developments in the Treatment of HIV/AIDS . The 51-page report, published by Griffin Securities, Inc., provides a comprehensive review of the major developments in the treatment of HIV/AI
FOSTER CITY, Calif. -- Gilead Sciences , Inc. (Nasdaq:GILD) today announced that the company has received early termination by the United States Federal Trade Commission (the FTC ) of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the licensing agreement annou
NEW YORK -- Xenomics, Inc. (OTCBB:XNOM), a developer of next-generation medical DNA technologies, has filed a provisional patent in Italy for its breakthrough technology enabling the detection of Transrenal-DNA of HIV and tuberculosis through the safe and non-invasive process of urine sampling. The Italian patent appli
CARLSBAD, Calif. -- The Immune Response Corporation (Nasdaq:IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis, announced today that the Company s lead HIV product candidate, REMUNE(R) (gp120-depleted HIV-1 immunogen), will be included in a clin
SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD) announced today that it has been advised by Qualtran LLC, a contract research organization (CRO) managing clinical trials for Aethlon in India , that both the Government of India and Industry are supportive of Aethlon s upcoming HIV and Hepatitis-C trials.
EMERSON, N.J. -- Energex Systems, Inc. announced today that a clinical trial has established that its HemoModulator technology was safe and highly effective in reducing viral loads in trial participants inflicted with Hepatitis C. There were no reported adverse events related to the treatment. The trial was conducted u
SAN FRANCISCO -- A stark landscape evocative of devastation and the promise of renewal has been selected from over 200 entries in an international design competition for the National AIDS Memorial in San Francisco s Golden Gate Park. Titled Living Memorial, the winning design is a no holds-barred reality check for a di
NEW YORK, N.Y. -- Xenomics, Inc. (OTCBB:XNOM), a developer of next-generation medical DNA technologies, has announced clinical results that demonstrate for the first time the ability to detect tuberculosis Transrenal-DNA (Tr-DNA) in the urine of infected patients. This application of the Company s patented technology p
FOSTER CITY, Calif. -- Gilead Sciences , Inc. (Nasdaq:GILD) today announced that the company s global Access Program for HIV medicines is being expanded to include additional countries in the Caribbean and Latin America. The Gilead Access Program makes Gilead s Truvada(R) (emtricitabine and
WOODLAND HILLS, Calif. -- Following the initiation of a Phase I, FDA-approved clinical trial at the Georgetown University Medical Center to study an investigational treatment for AIDS patients failing to respond to standard antiretroviral drugs, i.e., drug resistance, Dr. Joseph A. Bellanti MD, Chief Scientific Officer
RALEIGH, N.C. -- Grant Life Sciences (OTC Bulletin Board: GLIF): -- Grant Life Sciences controls exclusive rights to rapid tests for HIV-1, HIV-2 and Dengue Fever, as well as a proprietary colloidal gold reagent, a key ingredient commonly used by leading manufacturers of rapid tests as a detectable label -- Agreemen
WOODLAND HILLS, Calif. -- Advanced Biotherapy, Inc. (OTCBB: ADVB) announced today that The United States Patent and Trademark Office has assigned U.S. Patent No. 6,863,890 to the Company for use of antibodies to Tumor Necrosis Factor-alpha (TNF-a), Interferon-Gamma (IFN-g) and Interferon-alpha (IFN-a) for the treatment
EAST BRUNSWICK, N.J. -- Savient Pharmaceuticals, Inc. (NASDAQ:SVNT), an emerging specialty pharmaceuticals company focused on addressing the unmet medical needs in both niche and broader markets, announced today that its dose ranging Phase 2 trial of Prosaptide will be terminated. This trial was designed to test the sa
CARLSBAD, Calif. -- The Immune Response Corporation (NASDAQ:IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis, announced today results from two European studies with REMUNE(R), the Company s lead HIV immune-based therapy. Results from a Phase I
GERMISTON, South Africa -- The South African National Association of People Living with HIV and AIDS (NAPWA) expelled fifteen Treatment Action Campaign (TAC) plants from both its leadership and from the organization at its national conference in February. The decision to expel the TAC from its ranks was taken by a unan
NEW YORK -- Xenomics, Inc. (OTCBB:XNOM), a developer of next-generation DNA detection technologies, announced new clinical results that demonstrate for the first time ever the detection of proviral HIV-DNA in the urine of AIDS patients. The discovery was made at the Company s joint venture with the National Institute f
-- Study Suggests That SQLs Could Be Used in Combination With Other Antiretroviral Drugs In Multi Therapy Regimens PARIS -- BioAlliance Pharma, a biopharmaceutical company focused on the field of drug resistance, announced today results presented at the 12th Conference on Retroviruses and Opportunistic Infections (CROI
MENLO PARK, Calif.-- Geron Corporation (Nasdaq: GERN) announced today the presentation of studies showing that its small molecule telomerase activators, GRN139951 and GRN140665, enhance the functional activity of immune cells from HIV/AIDS donors. The research, presented at the 2005 Palm Springs Symposium on HIV/AIDS,
HORSHAM, Pa.-- Nucleonics, Inc., a biotechnology company focused on the development of novel expressed RNA interference-based (eiRNA) therapeutics, announced today that it has filed with the Polish Patent Office prior art citations that it believes relevant to the consideration of Benitec s Patent Application Number PL
WOODLAND HILLS, Calif.-- Advanced Biotherapy, Inc. (OTCBB:ADVB), dedicated to pioneering the development and use of therapeutic antibodies, announced today that Dr. Yehuda Shoenfeld, one of the world s foremost immunologists and Director of the Center for Autoimmune Diseases at the Sheba Medical Center, Israel s larges
CARLSBAD, Calif. -- The Immune Response Corporation (Nasdaq:IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS), announced today a new Phase II study to investigate the long-term safety, mechanism-of-action, and utility of a quarterly dosing
SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD) announced that its Chief Scientific Officer, Dr. Richard Tullis will present today at the 25th Annual Dialysis Conference, being held at the Tampa Convention Center. The presentation is scheduled to begin at 3:00 p.m. EST. Dr. Tullis will discuss how the multi-pathogen, m
LAS VEGAS -- Samaritan Pharmaceuticals Inc. (AMEX:LIV): -- Only Small Cap in Race to Be First to Market with Pill to Block AIDS Virus Entry -- Selected Sites Being Readied to Commence Monotherapy Trial 2Q05 -- Industry Analyst Project a Successful Drug Could Generate Sales as Much as $500-$700 Million a Year Samari
BOSTON -- Gilead Sciences (Nasdaq:GILD) today announced the presentation of preliminary 48-week data from the RAVE (Randomized Abacavir Viread Evaluation) study at the 12th Conference on Retroviruses and Opportunistic Infecti
-- Data Marks First Proof of Anti-Viral Activity by a Microbicide after Human Application LEXINGTON, Mass.-- Findings presented at the 12th Conference on Retroviruses and Opportunistic Infections demonstrated that PRO 2000, a candidate topical microbicide under development by Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV
BOYNTON BEACH, Fla. -- Nutra Pharma Corp., (OTCBB: NPHC) a biotechnology holding company that owns rights to intellectual property related to the development of drugs for HIV and Multiple Sclerosis, has today announced that an interview with Rik J Deitsch, President and CEO of Nutra Pharma by Wall Street Reporter is no
FOSTER CITY, Calif. -- Gilead Sciences (Nasdaq:GILD) today announced that the European Commission has granted a Marketing Authorisation for Truvada(R) (emtricitabine and tenofovir disoproxil fumarate) in all 25 member states of the European Union. Truvada combines the company s anti-HIV medications E
SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD) announced today that it plans to initiate clinical trials to treat patients infected with the Hepatitis-C Virus (HCV) in India . According to the World Health Organization , HCV is a global disease with approximately 170 million persons or 3% of the world s populatio
MEDFORD, NY--Chembio Diagnostics, Inc. (OTCBB:CEMI) today announced that it submitted an application to the U.S. Food and Drug Administration ( FDA ) for Pre-Market Approval of its Sure Check(TM) HIV and HIV Stat-Pak rapid HIV tests. Both Sure Check HIV and HIV Stat-Pak are rapid test devices that can detect antibodies
WOODLAND HILLS, Calif.--Advanced Biotherapy, Inc. (OTCBB:ADVB), dedicated to pioneering the development and use of therapeutic antibodies, responds to breaking news regarding a recently discovered new resistant strain of the HIV virus that was detected in New York City, as reported by CBS affiliate WCBS-TV New York on
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c13022) has announced the addition of HIV - Benchmarking Rapid Antiretroviral Uptake to their offering. Historically, HIV antiretrovirals have differed markedly in their speed of market uptake. Now, to win market share in an already matu
DUBLIN, Ireland -- This Report offers a comprehensive review of the global protease market. The Report discusses strategies to design peptidomimetic and non-peptidomimetic competitive inhibitors, as well as other types of inhibitors. The main disease areas where proteases or their inhibitors are involved include infect
MEDFORD, N.Y. -- Chembio Diagnostics, Inc. (OTCBB: CEMI), a leading developer, manufacturer and marketer of HIV rapid test products, announced today that The New England Journal of Medicine published an article titled Cost Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral Therapy. The articl
NEW YORK -- The Global Business Coalition on HIV/AIDS (GBC), a network of 185 international companies committed to fighting the AIDS pandemic, released a statement today applauding a new report recommending that virtually all Americans be tested routinely for the AIDS virus. If such a shift were to occur, Americans wou
CARLSBAD, Calif. -- The Immune Response Corporation (Nasdaq:IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS), announces that Robert E. Knowling, Jr. has joined the Company s Board of Directors as Chairman. Mr. Knowling may be best known f
STANFORD, Calif. -- Expanding HIV screening would be a relatively cost-effective way to increase life expectancy and decrease disease transmission. That is the conclusion of researchers at the Veterans Affairs Palo Alto Health Care System and Stanford University School of Medicine who conducted a cost-effectiveness ana
BETHESDA, Md. -- Chindex International, Inc. (Nasdaq:CHDX), the largest independent American distributor of Western healthcare products and services in China , announced today that its German subsidiary, Chindex China-Export, GmbH, has been awarded a contract to supply medical equipment to hospitals in two Chinese prov
SEATTLE -- Corixa Corporation (Nasdaq:CRXA), a developer of immunotherapeutics, today announced that GlaxoSmithKline Biologicals (GSK Bio) has received European approval for its hepatitis B vaccine, Fendrix(R), containing Corixa s MPL(R) adjuvant. Fendrix, GSK Bio s novel vaccine containing Corixa s MPL adj
SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD) announced today that it has retained Sunil Sawhney, the former Director of Boston Scientific India , and other regulatory advisors from Qualtran, LLC to manage clinical studies to treat patients infected with HIV (the AIDS virus) in India. Aethlon CEO, James A.
NEW YORK & AMSTERDAM -- The Department of Development Cooperation of the Netherlands Ministry of Foreign Affairs (DGIS), the leading Dutch government agency for foreign assistance, recently awarded a grant of 2 million euros to the TB Alliance, a non-profit drug development endeavor leading global efforts to develo
FOSTER CITY, Calif.-- Gilead Sciences (Nasdaq:GILD) today announced preliminary 48-week data from the company s Study 934. This study was designed to compare a regimen of Viread (R) ( tenofovir disoproxil fumarate), Emtriv
SAN CARLOS, Calif.-- NeurogesX today announced it has appointed Karen J. Harder as Senior Vice President, Regulatory and Technical Operations. Ms. Harder, who has many years experience in managing clinical and regulatory affairs for drug development and medical device projects, is responsible for all regulatory and tec
LAS VEGAS -- Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs announced today it has selected LabConnect to provide central lab testing services for its upcoming Monotherapy trial for HIV patients. The trial entitled A multi-center, double-blind, randomized, placebo-controlled, study of orally
MELBOURNE, Australia-- Norwood Abbey Limited (OTC:NABYF) (ASX:NAL): Key Points: -- Patent Granted in South Africa (patent number 2003/2931) -- Granted Claims Cover Key Aspects of the Immunology Technology Norwood Abbey Limited (OTC:NABYF) (ASX:NAL) announces that another patent relating to its immunology technology has
DUBLIN, Ireland-- Research and Markets (http://www.researchandmarkets.com/reports/c12183) has announced the addition of Stakeholder Opinions: HIV Vaccines - The Emperor Has No Clothes to their offering. In December 2004, 35.9-44.3 million individuals were currently living with HIV/AIDS. In the same year, 2.8-3.5 millio
RALEIGH, N.C.-- Under proposed terms, Grant Life Sciences will control exclusive rights to rapid tests for HIV-1, HIV-2 and Dengue Fever, as well as a proprietary colloidal gold reagent, a key ingredient commonly used by leading manufacturers of rapid tests as a detectable label The Company anticipates that the Agreeme
SEATTLE & WHITEHOUSE STATION, N.J.-- Public/Private Partnership of Merck and HIV Vaccine Trials Network To Conduct First Efficacy Test of Merck Vaccine Candidate The HIV Vaccine Trials Network (HVTN) and Merck & Co. , Inc. today announced that they have begun a collaborative Phase II proof-of-concept study usin
DUBLIN, Ohio -- Conference Call 11:00 a.m., January, 19, 2005 to Discuss Subsidiary Formation Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that it has formed a new corporation, CIRA Biosciences, Inc. (CIRA Bio), to
SAN FRANCISCO -- International efforts towards developing a vaccine against HIV infection have been given a much-needed boost by the publication today of the Global HIV/AIDS Vaccine Enterprise s scientific strategic plan, published online in the freely available, open-access global health journal PLoS Medicine. The Glo
OREGON CITY, Ore. -- The Hepatitis C Caring Ambassadors Program (HCCAP) proudly announces the Internet release of the newly updated 3rd edition of Hepatitis C Choices: Distinctive Viewpoints on Choices for Your Hepatitis C Journey. The book is authored by a team of 20 leading medical experts and patient advocates. Hepa
CARLSBAD, Calif. -- The Immune Response Corporation (Nasdaq:IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS), announces that the Company has completed two Phase II clinical trials, one in Italy and one in S
LAS VEGAS -- Samaritan Pharmaceuticals Inc. (AMEX:LIV): -- HIV Drug SP-01A (sPHirewall technology) Appears to Stop Viral Entry Early in the Infection Process Even Before Fusion Inhibitors Making It an Excellent Candidate to Combat HIV Drug Resistance -- Drug Resistance Remains the Single Most Important Reason for Virol
FREMONT, Calif. -- Abgenix, Inc. (Nasdaq: ABGX) announced today that it has received a milestone payment triggered by Human Genome Sciences filing of an Investigational New Drug application (IND) with the U.S. Food and Drug Administration ( FDA ) for a fully human monoclonal antibody to the CCR5 receptor (CCR5 mAb) cre
JOHANNESBURG, South Africa -- The Global Business Coalition on HIV/AIDS (GBC), a network of more than 170 international companies committed to fighting the AIDS pandemic released the following statement today on the death of Makgatho Mandela, the son of Nelson Mandela: Our thoughts and prayers are with the Mandela fami
PHILADELPHIA-- --Hemispherx Biopharma, Inc. (AMEX: HEB) announced today that its partner Esteve Laboratorios, Spain , initiated a clinical program to evaluate the antiretroviral effect of Ampligen in the treatment of patients infected by HIV-1 (with or without co-infection by HCV) and virological failure with a randomi
This information is designed to support, not replace, the relationship that exists between you and your doctor.